Status:
NOT_YET_RECRUITING
MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer
Lead Sponsor:
Fujian Cancer Hospital
Collaborating Sponsors:
Fujian Provincial Hospital
First Affiliated Hospital of Fujian Medical University
Conditions:
Endometrial Neoplasms
Eligibility:
FEMALE
18-80 years
Brief Summary
Molecular typing provides accurate information for the diagnosis, treatment and prognosis prediction of endometrial cancer, which has important clinical significance. However, due to its high cost and...
Detailed Description
In this project, 150 cases of endometrial cancer were retrospectively collected, and 200 cases of endometrial cancer will be prospectively collected. All patients were pathologically confirmed and und...
Eligibility Criteria
Inclusion
- •Pathologically confirmed as endometrial malignant tumor with complete pathological H＆E stained sections;
- Age ≥ 18 years and ≤ 80 years;
- No other malignant cancers was found;
- The complete immunohistochemical and second-generation sequencing results can be used for the molecular typing of ProMisE;
- Magnetic resonance examination was performed within 2 weeks before treatment, and there was at least one measurable lesion according to RECIST 1.1 Criteria.
Exclusion
- • The image quality is poor or the tumor is too small due to serious graphic artifact and degeneration, and the ROI cannot be accurately delineated;
- Patients who received any antitumor therapy before surgery;
- Diagnostic endometrial biopsy before MRI
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT06126393
Start Date
January 1 2024
End Date
June 30 2027
Last Update
November 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014